Sun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The launch of Leqselvi for alopecia has been well-received, with further growth anticipated from upcoming launches like Unloxcyt. This marks a significant shift in the company's revenue streams.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6reqMC
via IFTTT
No comments:
Post a Comment